Skip to main content
. 2011 Dec 20;21(7):1625–1638. doi: 10.1093/hmg/ddr600

Figure 9.

Figure 9.

Delayed ICV injection yields intermediate weight gain and survival. (A) SMNΔ7 SMA mice treated at P4 with 54 μg MO/g body mass (‘high dose’ equivalent) had increased weight gain when compared with SMNΔ7 SMA controls, but was less than the weight gain displayed by P0 MO-treated SMNΔ7 SMA animals [P30 mean 10.6 ± 1.5 g (P4) versus 13.6 ± 1.0 g (P0)]. (B) P4 ICV MO-injected animal survival was also increased (median 41 ± 14.2 days, maximum 78 days) when compared with scMO-injected animals (15 ± 1.1 days; log-rank P< 0.001), but was decreased when compared with SMNΔ7 SMA animals treated at P0 with high-dose MO (112 ± 6.6 days, maximum 153 days, log-rank P< 0.01). (C) SMNΔ7 SMA mice were injected with P4 MO by FV. Survival was modestly extended when compared with scMO-injected animals, and there was a decreased survival when compared with animals injected by P4 ICV MO (median 21 ± 0.354 days, log-rank P< 0.014).